These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 19414635)

  • 41. Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice.
    Christensen EI; Zhou Q; Sørensen SS; Rasmussen AK; Jacobsen C; Feldt-Rasmussen U; Nielsen R
    J Am Soc Nephrol; 2007 Mar; 18(3):698-706. PubMed ID: 17287429
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease.
    Lubanda JC; Anijalg E; Bzdúch V; Thurberg BL; Bénichou B; Tylki-Szymanska A
    Genet Med; 2009 Apr; 11(4):256-64. PubMed ID: 19265719
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quantitative determination of globotriaosylceramide by immunodetection of glycolipid-bound recombinant verotoxin B subunit.
    Zeidner KM; Desnick RJ; Ioannou YA
    Anal Biochem; 1999 Feb; 267(1):104-13. PubMed ID: 9918661
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies.
    Eng CM; Banikazemi M; Gordon RE; Goldman M; Phelps R; Kim L; Gass A; Winston J; Dikman S; Fallon JT; Brodie S; Stacy CB; Mehta D; Parsons R; Norton K; O'Callaghan M; Desnick RJ
    Am J Hum Genet; 2001 Mar; 68(3):711-22. PubMed ID: 11179018
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Current management of Fabry disease].
    Cochat P; Liutkus A; Dubourg L; Levade T
    Nephrol Ther; 2006 Jan; 2 Suppl 2():S167-71. PubMed ID: 17373218
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-Term Clinical-Pathologic Results of Enzyme Replacement Therapy in Prehypertrophic Fabry Disease Cardiomyopathy.
    Frustaci A; Verardo R; Galea N; Alfarano M; Magnocavallo M; Marchitelli L; Sansone L; Belli M; Cristina M; Frustaci E; Russo MA; Chimenti C
    J Am Heart Assoc; 2024 Apr; 13(8):e032734. PubMed ID: 38563373
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease.
    Bénichou B; Goyal S; Sung C; Norfleet AM; O'Brien F
    Mol Genet Metab; 2009 Jan; 96(1):4-12. PubMed ID: 19022694
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Promoter-specific lentivectors for long-term, cardiac-directed therapy of Fabry disease.
    Lee CJ; Fan X; Guo X; Medin JA
    J Cardiol; 2011 Jan; 57(1):115-22. PubMed ID: 20846825
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vascular abnormalities and cardiomyocyte lipofuscin deposits in endomyocardial biopsy specimens of heart transplant recipients: are they related to the development of cardiac allograft vasculopathy?
    Zakliczynski M; Nozynski J; Konecka-Mrowka D; Krynicka-Mazurek A; Swierad M; Maruszewski M; Przybylski R; Zembala M
    J Thorac Cardiovasc Surg; 2009 Jul; 138(1):215-21, 221.e1-3. PubMed ID: 19577082
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Fabry disease].
    Jakubowska E; Ryba M; Hruby Z
    Przegl Lek; 2006; 63(4):218-9. PubMed ID: 17080745
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial.
    Wijburg FA; Bénichou B; Bichet DG; Clarke LA; Dostalova G; Fainboim A; Fellgiebel A; Forcelini C; An Haack K; Hopkin RJ; Mauer M; Najafian B; Scott CR; Shankar SP; Thurberg BL; Tøndel C; Tylki-Szymańska A; Ramaswami U
    PLoS One; 2015; 10(5):e0124987. PubMed ID: 25955246
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The heart in Anderson Fabry disease.
    Kampmann C; Wiethoff CM; Perrot A; Beck M; Dietz R; Osterziel KJ
    Z Kardiol; 2002 Oct; 91(10):786-95. PubMed ID: 12395219
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: utility for Fabry disease diagnosis and treatment monitoring.
    Rozenfeld PA; De Francesco NP; Borrajo GJ; Ceci R; Fossati CA
    Clin Chim Acta; 2009 May; 403(1-2):194-7. PubMed ID: 19268437
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study.
    Deegan PB; Goker-Alpan O; Geberhiwot T; Hopkin RJ; Lukina E; Tylki-Szymanska A; Zaher A; Sensinger C; Gaemers SJM; Modur V; Thurberg BL; Sharma J; Najafian B; Mauer M; DasMahapatra P; Wilcox WR; Germain DP
    Mol Genet Metab; 2023 Feb; 138(2):106963. PubMed ID: 36481125
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nailfold capillaroscopy: Specific features in Fabry disease.
    Wasik JS; Simon RW; Meier T; Steinmann B; Amann-Vesti BR
    Clin Hemorheol Microcirc; 2009; 42(2):99-106. PubMed ID: 19433883
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.
    Marshall J; Ashe KM; Bangari D; McEachern K; Chuang WL; Pacheco J; Copeland DP; Desnick RJ; Shayman JA; Scheule RK; Cheng SH
    PLoS One; 2010 Nov; 5(11):e15033. PubMed ID: 21124789
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enzyme replacement therapy for Fabry disease: morphologic and histochemical changes in the urinary sediments.
    Utsumi K; Mitsuhashi F; Asahi K; Sakurazawa M; Arii K; Komaba Y; Katsumata T; Katsura K; Kase R; Katayama Y
    Clin Chim Acta; 2005 Oct; 360(1-2):103-7. PubMed ID: 16112661
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enzyme replacement therapy in severe Fabry disease with renal failure: a 1-year follow-up.
    Tsambaos D; Chroni E; Manolis A; Monastirli A; Pasmatzi E; Sakkis T; Davlouros P; Goumenos D; Katrivanou A; Georgiou S
    Acta Derm Venereol; 2004; 84(5):389-92. PubMed ID: 15370707
    [TBL] [Abstract][Full Text] [Related]  

  • 59. When should cardiologists suspect Anderson-Fabry disease?
    Gambarin FI; Disabella E; Narula J; Diegoli M; Grasso M; Serio A; Favalli BM; Agozzino M; Tavazzi L; Fraser AG; Arbustini E
    Am J Cardiol; 2010 Nov; 106(10):1492-9. PubMed ID: 21059442
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Fabry disease: diagnostic due of substitutive enzyme-therapy].
    Barbey F; Widmer U; Burnier M; Lidove O
    Rev Med Suisse Romande; 2002 Sep; 122(9):449-53. PubMed ID: 12422475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.